bibliographicCitation |
Mizugaki H, Yamamoto N, Murakami H, Kenmotsu H, Fujiwara Y, Ishida Y, Kawakami T, Takahashi T. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Investigational New Drugs. 2016 Jul 01;34(5):596–603. doi: 10.1007/s10637-016-0371-6. |